Our Expedio™ Hereditary Cancer and Inspexion™ Pharmacogenetics tests are physician-directed genetic screenings that offer a cost-effective strategy designed to achieve optimized, personalized care for your patients.

23andMe has more than 12 million customers worldwide. Our Health + Ancestry Service allows individuals to acquire this information from the privacy of their own homes, without medical requisition. Nearly 30% of consumers who undergo direct-to-consumer (DTC) genetic testing choose to share their reports with healthcare providers to inform conversations about their health.1,2,3 Our Healthcare Professionals community was created to help U.S. providers and their patients navigate genetics together in order to make important informed decisions about prevention, treatment and healthy living.

23andMe is a human genome research company enabling users to study their ancestry, genealogy, and inherited traits. A startup co-founded by Linda Avey and Anne Wojcicki, the wife of Google co-founder Sergey Brin, 23andMe has plans to make the human genome searchable. Brin, along with Google, gave 23andMe $3.9 million as part of a series A in May of 2007. The company was named after the number of chromosome pairs in humans. They aim to help people understand what their genes mean by indexing them and highlighting significant findings. 23andMe allows its clients/users to study their ancestry, genealogy, and inherited traits. The company also markets to researchers and scientists, for whom they provide neatly categorized and easily searchable data. One reason the Google investment in 23andMe made sense, was that this company could enable the search giant to index another facet of the world's information. With the Biotech and Health Care industries growing rapidly, 23andMe could help Google get and maintain a market hold in these already multi-billion dollar areas.